Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




SLAS Hosts First Annual China Conference and Exhibition

By LabMedica International staff writers
Posted on 27 Dec 2010
The newly merged Society for Laboratory Automation and Screening (SLAS; St. More...
Charles, IL, USA) hosted its First Annual China Conference and Exhibition in Shanghai (China), at the Shangri-La Hotel, on December 7-9, 2010. The newly launched event set the framework for future SLAS endeavors in Asia Pacific.

The meeting combined a series of presentations on new technologies and experimental approaches for hit and lead identification with the opportunity for local scientists to network with in an informal and engaging environment.

The conference hosted 25 exclusive scientific lectures presented by eminent scientists. Christopher Lipinski, PhD, from Melior Discovery (Exton, PA, USA) discussed the issue of compound failure in preclinical and clinical development and strategies to reduce this failure rate through improvements to the physiochemical properties of drug candidates.

Wei Zhang PhD, National Institutes of Health Chemical Genomics Center (NIH; Bethesda, MD, USA) presented on the use of cellular phenotypic screens for lead identification to enable the identification of molecules with improved efficacy.

At the exhibition, TTP Labtech (Royston, United Kingdom) launched the Mirrorball, a new laser scanning microplate cytometer designed primarily for the study of antibody/antigen interactions. The new instrument offers increased sensitivity and multiplexing capability compared to existing instruments.

As a complimentary benefit to conference participants, SLAS partnered with the Shanghai Zhangjiang Technology Park (Shanghai, China) for a private pre-event function highlighted by three additional scientific lectures. The primary presentation was given by Xin Xie, PhD, head of assay development, Chinese National Center for Drug Screening (Shanghai, China).

A guided tour of the technology park was given to meeting participants. The park houses 110 research and development institutions and 327 companies including leading pharmaceutical companies.

According to SLAS scientific program committee chair Steven Rees at GlaxoSmithKline (Stevenage, United Kingdom), the conference was "phenomenally successful.” He added, "Bringing SLAS to Shanghai has demonstrated the interest and expertise in drug discovery in China, and the enthusiasm of the local scientists to partner with the SLAS community.”

Related Links:

Society for Laboratory Automation and Screening
GlaxoSmithKline
Melior Discovery
TTP Labtech


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.